In male Sprague-Dawley rats given 25 mg/kg intraperitoneally, SBI-0206965 reached a brain extracellular-fluid Cmax of 358.33 ± 205.39 ng/mL (mean ± SD). Plasma elimination was rapid, and oral exposure gave a relative bioavailability of 0.15 compared with intraperitoneal dosing. This study measured exposure rather than antitumor efficacy. [3]
In six-month-old 5XFAD Becn1 F121A/F121A mice, SBI-0206965 at 2 mg/kg intraperitoneally once daily for 7 days increased brain Aβ42 relative to vehicle. This reversed the reduced amyloid signal associated with the autophagy-active Becn1 mutation; it does not support a cognitive benefit from SBI-0206965. [4]
Brain exposure and limited relative oral availability
Animal study · Male Sprague-Dawley rats, 200–250 g, 6–7 weeks; brain extracellular fluid and plasma pharmacokinetics [3]
Following 25 mg/kg intraperitoneal SBI-0206965, drug was detected in brain extracellular fluid. Table 1 reports short plasma half-lives and an oral-to-intraperitoneal relative bioavailability of 0.15. These are exposure data, without tumor efficacy or absolute oral bioavailability determination.
Conditions shared by the study groups
- Frequency
- Single administration
- Treatment course
- Single-dose PK
- Rat intraperitoneal exposure
- Model: Male Sprague-Dawley rats; N = 5
- Route: Intraperitoneal
- Reported limits: Rat formulation not stated in read main text. Peak time and sampling schedule excluded due to internal discrepancies.
- Rat oral exposure
- Model: Male Sprague-Dawley rats; N = 4
- Route: Oral
- Reported limits: Rat oral formulation and exact administration technique are not specified in the read main text.
Methods and source locations
Compound reported in the paper: SBI-0206965
Results apply to the named research compound in the reported model and conditions.
Figure 1A-B; Table 1; rat microdialysis, drug administration, bioanalysis and statistical-analysis methods; BBB/systemic PK Results
Rat brain extracellular-fluid maximum concentration after 25 mg/kg i.p.: Table 1 non-compartmental parameters; Figure 1A caption N = 5. — Table 1: Cmax row, Brain ECF (i.p.) column; Figure 1A caption
Rat plasma elimination half-life: Table 1; Figure 1 caption: i.p. N = 5, oral N = 4. — Table 1: T1/2 row; Figure 1B caption
Relative oral availability referenced to intraperitoneal administration: Comparison of oral and i.p. plasma AUC; no i.v. arm, not absolute bioavailability. — Table 1 final row; BBB/systemic PK Results
Rat intraperitoneal exposure · Figure 1A-B captions; Table 1; Drug administration and sampling protocol
Rat oral exposure · Figure 1B caption; Table 1; BBB/systemic PK Results
SBI-0206965 reverses reduced brain Aβ42 in an autophagy-active mouse model
Animal study · Six-month-old 5XFAD Becn1 F121A/F121A mice (Becn1 FA/FA); C57BL/6 background [4]
Seven days of SBI-0206965 increased total brain Aβ42 relative to vehicle, reversing the reduction associated with the autophagy-active Becn1 mutation. This inhibitor-control experiment is a limiting result; it does not show cognitive benefit from SBI-0206965 or establish exclusive ULK1 mediation.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Once daily
- Treatment course
- 7 days; tissues collected 4 h after final injection
- Vehicle
- PBS containing 50% DMSO
- SBI-0206965 treatment
- Model: Six-month-old 5XFAD Becn1 FA/FA mice; Figure 3E N = 5
- Reported limits: Sex for this cohort and randomization/blinding are not specified in the read relevant text; exact effect size not tabulated.
Methods and source locations
Compound reported in the paper: SBI-0206965
Results apply to the named research compound in the reported model and conditions.
Figure 3E image/caption; Results: Becn1 F121A decreases amyloid accumulation; Methods: Drug treatment, Dot blot assay, Statistical analyses
Total brain Aβ42 immunoreactivity: Aβ42 dot blot normalized to Ponceau S; two-tailed unpaired Student’s t-test in Statistical analyses. — Figure 3E image and caption; Dot blot assay; Statistical analyses
SBI-0206965 treatment · Figure 3E and caption; Methods: Drug treatment, Dot blot assay, Statistical analyses